Prolonged local retention of vancomycin achieved by a multivesicular liposomes in thermoresponsive gel system for the prevention and treatment of intervertebral disc infection
Zhencheng Gao , Hongxia Fan , Lutong He , Yu Zhang , Tian Yin , Haibing He , Xing Tang , Yanjiao Wang , Jingxin Gou
{"title":"Prolonged local retention of vancomycin achieved by a multivesicular liposomes in thermoresponsive gel system for the prevention and treatment of intervertebral disc infection","authors":"Zhencheng Gao , Hongxia Fan , Lutong He , Yu Zhang , Tian Yin , Haibing He , Xing Tang , Yanjiao Wang , Jingxin Gou","doi":"10.1016/j.colsurfb.2025.114593","DOIUrl":null,"url":null,"abstract":"<div><div>The therapeutic efficacy of intervertebral disc (IVD) infections treated with intravenous vancomycin (VCM) is often limited by inadequate blood supply to the IVD. In this study, we developed a localized and sustained-release drug delivery system for the intradiscal administration of VCM. First, VCM-loaded multivesicular liposomes (VCM-MVLs) were prepared using a two-step emulsification process, and we investigated the effects of the preparation process and formulation composition on the quality of the MVLs. The prepared MVLs exhibited an encapsulation efficiency of 92.08 ± 6.44 %, a particle size of 30.35 μm, and a sustained release over 12 days. Subsequently, VCM-MVLs were incorporated with PLGA-PEG-PLGA (PPP) to create a thermosensitive hydrogel composite formulation (VCM-MVL-PPP), which demonstrated a gelling temperature of 28.4°C and exhibited prolonged sustained release over 20 days. The antimicrobial activity of VCM-MVL-PPP was maintained for an extended duration of 21 days. Additionally, the VCM-MVL-PPP demonstrated an optimal retention capacity of 14 days in the <em>in vivo</em> retention assay. <em>In vivo</em> safety results confirmed the high biocompatibility and negligible toxicity of the formulation. In conclusion, the presence of PPP as a secondary release barrier for the drug released from MVLs allowed VCM-MVL-PPP to exhibit prolonged drug release and retention in the IVDs compared to VCM-MVLs. Our findings provide a valuable reference for peptide delivery and the treatment of disc infections.</div></div>","PeriodicalId":279,"journal":{"name":"Colloids and Surfaces B: Biointerfaces","volume":"251 ","pages":"Article 114593"},"PeriodicalIF":5.4000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces B: Biointerfaces","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927776525001006","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOPHYSICS","Score":null,"Total":0}
引用次数: 0
Abstract
The therapeutic efficacy of intervertebral disc (IVD) infections treated with intravenous vancomycin (VCM) is often limited by inadequate blood supply to the IVD. In this study, we developed a localized and sustained-release drug delivery system for the intradiscal administration of VCM. First, VCM-loaded multivesicular liposomes (VCM-MVLs) were prepared using a two-step emulsification process, and we investigated the effects of the preparation process and formulation composition on the quality of the MVLs. The prepared MVLs exhibited an encapsulation efficiency of 92.08 ± 6.44 %, a particle size of 30.35 μm, and a sustained release over 12 days. Subsequently, VCM-MVLs were incorporated with PLGA-PEG-PLGA (PPP) to create a thermosensitive hydrogel composite formulation (VCM-MVL-PPP), which demonstrated a gelling temperature of 28.4°C and exhibited prolonged sustained release over 20 days. The antimicrobial activity of VCM-MVL-PPP was maintained for an extended duration of 21 days. Additionally, the VCM-MVL-PPP demonstrated an optimal retention capacity of 14 days in the in vivo retention assay. In vivo safety results confirmed the high biocompatibility and negligible toxicity of the formulation. In conclusion, the presence of PPP as a secondary release barrier for the drug released from MVLs allowed VCM-MVL-PPP to exhibit prolonged drug release and retention in the IVDs compared to VCM-MVLs. Our findings provide a valuable reference for peptide delivery and the treatment of disc infections.
期刊介绍：
Colloids and Surfaces B: Biointerfaces is an international journal devoted to fundamental and applied research on colloid and interfacial phenomena in relation to systems of biological origin, having particular relevance to the medical, pharmaceutical, biotechnological, food and cosmetic fields.
Submissions that: (1) deal solely with biological phenomena and do not describe the physico-chemical or colloid-chemical background and/or mechanism of the phenomena, and (2) deal solely with colloid/interfacial phenomena and do not have appropriate biological content or relevance, are outside the scope of the journal and will not be considered for publication.
The journal publishes regular research papers, reviews, short communications and invited perspective articles, called BioInterface Perspectives. The BioInterface Perspective provide researchers the opportunity to review their own work, as well as provide insight into the work of others that inspired and influenced the author. Regular articles should have a maximum total length of 6,000 words. In addition, a (combined) maximum of 8 normal-sized figures and/or tables is allowed (so for instance 3 tables and 5 figures). For multiple-panel figures each set of two panels equates to one figure. Short communications should not exceed half of the above. It is required to give on the article cover page a short statistical summary of the article listing the total number of words and tables/figures.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
